Fig. 7
Recombinant irisin administration ameliorated renal fibrosis in FAN mice. a Irisin injection (200 μg kg−1, ip daily for 2 weeks) achieved > 2 folds increase in serum (** P < 0.01 for FAN + irisin vs. Sham or FAN group, n = 5 per group, one-way ANOVA with Bonferroni’s multiple comparison test). b Representative images of PAS staining showing less tubule dilation, atrophy and brush-board loss in FAN mice treated with recombinant irisin. c Sirius red staining revealing collagen deposition decreased in FAN mice treated with irisin. Quantitative analysis of interstitial collagen in different groups as indicated. ** P < 0.01 for FAN vs. Sham, * P < 0.05 for FAN + irisin vs. FAN, and ## P < 0.01 for FAN + irisin vs. Sham. Data was presented as mean ± s.e.m. (n = 5 per group, one-way ANOVA with Bonferroni’s multiple comparison test). Scale bars, 100 μm. d Kidney function (serum creatinine) was assessed in FAN mice after irisin treatment. e: Western blots showing fibrotic protein expression in kidneys from FAN mice treated with irisin. Quantitative measurements of Fibronectin (FN), Collagen 1A and α-SMA protein expression in kidneys from each group as indicated. * P < 0.05 or ** P < 0.01 for FAN vs. Sham and # P < 0.05 for FAN + irisin vs. FAN (n = 5 per group, one-way ANOVA with Bonferroni’s multiple comparison test). f and g Real-time qPCR analysis of enzymes expression in glycolysis f and fatty acid oxidation g pathway. Data were presented as mean ± s.e.m.; * P < 0.05 or ** P < 0.01 for FAN vs. Sham and # P < 0.05 for FAN + irisin vs. FAN (n = 5 per group, one-way ANOVA with Bonferroni’s multiple comparison test)
